Compare Abbott Laboratories (ABT) vs Archer Aviation Inc (ACHR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Archer Aviation Inc — how do they compare? Abbott Laboratories trades at $95.63 (market cap $166.94B), while Archer Aviation Inc trades at $4.85 (market cap $3.76B). The key difference: Abbott Laboratories is far larger — about 44.4× Archer Aviation Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Archer Aviation Inc pays none. Which is the better fit depends on your goals.
| ABT | ACHR | |
|---|---|---|
Market Cap | $166.94B | $3.76B |
Sector | Health | Industrials |
52-Week High | $136.62 | $13.64 |
52-Week Low | $82.57 | $4.68 |
Enterprise Value | $193.69B | $2.11B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Archer Aviation (ACHR) trades at $5.37, up 7.83% with a bearish technical signal despite recent momentum. The company shows severe financial strain with -$618.2M net income on minimal $300K revenue in 2025, though analyst sentiment remains optimistic with 78% buy ratings. Recent news highlights progress toward FAA certification for its Midnight eVTOL aircraft, with commercialization targeted for 2028 and a $6B order book providing long-term potential.
The stock presents high-risk speculative potential with significant execution hurdles. While regulatory progress and major partnerships with United Airlines and Stellantis support the bullish case, persistent cash burn and negative margins require substantial capital raises. Investors face binary outcomes dependent on successful certification and commercial deployment timelines against intense competition in the emerging eVTOL market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Archer Aviation Inc
Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.
Read more on ACHR →
